Optimal Sequential Enrichment Designs for Phase Ⅱ Clinical Trials

来源 :上海交通大学 | 被引量 : 0次 | 上传用户:itwmh
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  In the early phase development of molecularly targeted agents(MTAs),a commonly encountered situation is that the MTA is expected to be more effective for a certain biomarker subgroup,say marker-positive patients,but there is no adequate evidence to show that the MTA does not work for the other subgroup,i.e.,marker-negative patients.
其他文献
Although complete randomization ensures covariate balance on average,the chance for observing significant differences between treatment and control covariate distributions is high especially with many
We consider the problem associated to recovering the block structure of an Ising model given independent observations on the binary hypercube.
Testing for white noise is a classical yet important problem in statistics,especially for diagnostic checks in time series modeling.
This talk discusses the average value-at-risk(AVaR)criterion for finite horizon semi-Markov decision processes(SMDPs)in continuous-time.
In this talk,I will give some kinds of risk model with dependence structure,and some criteria under which we discuss the optimization problems.
Data Science programs,including academic,professional,short course and boot-camps,now abound worldwide.
As the treatments for breast cancer improve,disease free survival time is extensively prolonged and pharmaceutical developer faces a new challenge in clinical trial design and conduct based on long te
会议
We propose a dynamic network model for the evolution of an open animal population that is subject to an environmental catastrophe.
The primary objective of cancer phase Ⅰ studies is to determine the maximum tolerated dose(MTD).
In this talk,we will talk about embedding a non-parametric multiple change-point problem into a parametric framework.